NIEHS/FDA CLARITY-BPA research program update

作者：Heindel Jerrold J^*; Newbold Retha R; Bucher John R; Camacho Luisa; Delclos K Barry; Lewis Sherry M; Vanlandingham Michelle; Churchwell Mona I; Twaddle Nathan C; McLellen Michelle; Chidambaram Mani; Bryant Matthew; Woodling Kellie; da Costa Goncalo Gamboa; Ferguson Sherry A; Flaws Jodi; Howard Paul C; Walker Nigel J; Zoeller R Thomas; Fostel Jennifer; Favaro Carolyn; Schug Thaddeus T

来源：Reproductive Toxicology, 2015, 58: 33-44.

DOI：10.1016/j.reprotox.2015.07.075

• Bisphenol A
• NIEHS
• FDA
• NTP
• CLARITY-BPA
• Consortium
• Endocrine disruptors

Bisphenol A (BPA) is a chemical used in the production of numerous consumer products resulting in potential daily human exposure to this chemical. The FDA previously evaluated the body of BPA toxicology data and determined that BPA is safe at current exposure levels. Although consistent with the assessment of some other regulatory agencies around the world, this determination of BPA safety continues to be debated in scientific and popular publications, resulting in conflicting messages to the public. Thus, the National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), and U.S. Food and Drug Administration (FDA) developed a consortium-based research program to link more effectively a variety of hypothesis-based research investigations and guideline-compliant safety testing with BPA. This collaboration is known as the Consortium Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA). This paper provides a detailed description of the conduct of the study and a midterm update on progress of the CLARITY-BPA research program. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

• 出版日期2015-12